Preparation of peptide-loaded dendritic cells for cancer immunotherapy
- 100 Downloads
Dendritic cell-based vaccines are being evaluated in clinical trials to determine their ability to activate clinically relevant tumor antigen-specific immune responses. Although some groups isolate dendritic cells from peripheral blood, most have found it more efficient to generate large numbers from peripheral blood progenitors, particularly plastic adherent or CD14+ monocytes, in media supplemented with GM-CSF and IL-4. These DC may then be matured, if desired, and loaded with antigen, such as tumor-associated peptides, prior to administration. We describe the scheme that we are currently using to generate peptide-loaded dendritic cells for our clinical trials of cancer immunotherapy.
Index EntriesDendritic cells cancer immunotherapy
Unable to display preview. Download preview PDF.
- 3.Morse MA, Deng Y, Hull S, Coleman D, et al. (1999) A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5, 1331–1338.PubMedGoogle Scholar
- 11.Ruppert, J., Friedrichs, D., Xu, H., Peters, J.H. (1991) IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Immunobiol. 182, 449–464.Google Scholar